Non-contrast T1-mapping Detects Acute Myocardial Edema with High Diagnostic Accuracy: a Comparison to T2-weighted Cardiovascular Magnetic Resonance
Overview
Radiology
Authors
Affiliations
Background: T2w-CMR is used widely to assess myocardial edema. Quantitative T1-mapping is also sensitive to changes in free water content. We hypothesized that T1-mapping would have a higher diagnostic performance in detecting acute edema than dark-blood and bright-blood T2w-CMR.
Methods: We investigated 21 controls (55 ± 13 years) and 21 patients (61 ± 10 years) with Takotsubo cardiomyopathy or acute regional myocardial edema without infarction. CMR performed within 7 days included cine, T1-mapping using ShMOLLI, dark-blood T2-STIR, bright-blood ACUT2E and LGE imaging. We analyzed wall motion, myocardial T1 values and T2 signal intensity (SI) ratio relative to both skeletal muscle and remote myocardium.
Results: All patients had acute cardiac symptoms, increased Troponin I (0.15-36.80 ug/L) and acute wall motion abnormalities but no LGE. T1 was increased in patient segments with abnormal and normal wall motion compared to controls (1113 ± 94 ms, 1029 ± 59 ms and 944 ± 17 ms, respectively; p < 0.001). T2 SI ratio using STIR and ACUT2E was also increased in patient segments with abnormal and normal wall motion compared to controls (all p < 0.02). Receiver operator characteristics analysis showed that T1-mapping had a significantly larger area-under-the-curve (AUC = 0.94) compared to T2-weighted methods, whether the reference ROI was skeletal muscle or remote myocardium (AUC = 0.58-0.89; p < 0.03). A T1 value of greater than 990 ms most optimally differentiated segments affected by edema from normal segments at 1.5 T, with a sensitivity and specificity of 92 %.
Conclusions: Non-contrast T1-mapping using ShMOLLI is a novel method for objectively detecting myocardial edema with a high diagnostic performance. T1-mapping may serve as a complementary technique to T2-weighted imaging for assessing myocardial edema in ischemic and non-ischemic heart disease, such as quantifying area-at-risk and diagnosing myocarditis.
Kadoya Y, Mengesha B, Beauchesne L, Chong A, Labinaz M, Paterson D CJC Open. 2025; 7(2):141-144.
PMID: 40060205 PMC: 11886365. DOI: 10.1016/j.cjco.2024.11.016.
Singh R, Singh P, Kler T, Sharma S Cureus. 2024; 16(10):e72675.
PMID: 39618582 PMC: 11606607. DOI: 10.7759/cureus.72675.
Su Y, Liu X, Xie B, Zhang B, Yang Q, Yang M Rev Cardiovasc Med. 2024; 25(5):161.
PMID: 39076498 PMC: 11267212. DOI: 10.31083/j.rcm2505161.
Shanmuganathan M, Nikolaidou C, Burrage M, Borlotti A, Kotronias R, Scarsini R JACC Cardiovasc Imaging. 2024; 17(9):1044-1058.
PMID: 38970595 PMC: 11512682. DOI: 10.1016/j.jcmg.2024.05.007.
Monaco M, Stankowski K, Figliozzi S, Nicoli F, Scialo V, Gad A Medicina (Kaunas). 2024; 60(5).
PMID: 38792874 PMC: 11122968. DOI: 10.3390/medicina60050691.